Summary
PFE Chart
Pfizer's Comeback Is Underway
Pfizer's $7.7B cost-savings plan is boosting margins and EPS, offsetting COVID revenue declines and patent cliff concerns. Core business is growing 12% ex-COVID, with strength in oncology, vaccines, and internal medicine, plus a robust R&D pipeline. Major patent expirations threaten $15B+ in annual revenue by 2028, but Pfizer is aggressively pursuing pipeline and acquisition strategies.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings
PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.
Pfizer Inc. Dividends
 PFE 3 days ago Announced | Quarterly | $0.43 Per Share |
| PFE 2 months ago Paid | Quarterly | $0.43 Per Share |
| PFE 6 months ago Paid | Quarterly | $0.43 Per Share |
| PFE 8 months ago Paid | Quarterly | $0.42 Per Share |
| PFE 26 Jul 2024 Paid | Quarterly | $0.42 Per Share |
Pfizer Inc. Earnings
| 27 Oct 2025 (In 3 months) Date | | 0.87 Cons. EPS | - EPS |
| 5 Aug 2025 (In 1 week) Date | | 0.57 Cons. EPS | - EPS |
| 28 Jul 2025 28 Jul 2025 Date | | - Cons. EPS | - EPS |
| 29 Apr 2025 Date | | - Cons. EPS | - EPS |
| 4 Feb 2025 Date | | 0.49 Cons. EPS | 0.63 EPS |
| PFE 3 days ago Announced | Quarterly | $0.43 Per Share |
| PFE 2 months ago Paid | Quarterly | $0.43 Per Share |
| PFE 6 months ago Paid | Quarterly | $0.43 Per Share |
| PFE 8 months ago Paid | Quarterly | $0.42 Per Share |
| PFE 26 Jul 2024 Paid | Quarterly | $0.42 Per Share |
| 27 Oct 2025 (In 3 months) Date | | 0.87 Cons. EPS | - EPS |
| 5 Aug 2025 (In 1 week) Date | | 0.57 Cons. EPS | - EPS |
| 28 Jul 2025 28 Jul 2025 Date | | - Cons. EPS | - EPS |
| 29 Apr 2025 Date | | - Cons. EPS | - EPS |
| 4 Feb 2025 Date | | 0.49 Cons. EPS | 0.63 EPS |
Pfizer Inc. (PFE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Pfizer Inc. ever had a stock split?
Pfizer Inc. Profile
| Drug Manufacturers - General Industry | Healthcare Sector | Albert Bourla CEO | XWBO Exchange | US7170811035 ISIN |
| US Country | 81,000 Employees | 25 Jul 2025 Last Dividend | 17 Nov 2020 Last Split | 13 Aug 2012 IPO Date |
Overview
Pfizer Inc. is a global biopharmaceutical company with a rich history dating back to 1849. Based in New York, New York, Pfizer has established itself as a leader in the discovery, development, manufacture, marketing, distribution, and sale of innovative biopharmaceutical products. Serving a wide range of therapeutic areas, Pfizer's portfolio includes medicines and vaccines that address a variety of health concerns, from cardiovascular metabolic conditions and infectious diseases to chronic immune and inflammatory diseases. The company has a significant global footprint, operating across the United States, Europe, and other international markets, catering to wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and more. Through strategic collaboration agreements with entities like Bristol-Myers Squibb Company, Astellas Pharma US, Inc., Merck KGaA, and BioNTech SE, Pfizer continues to lead in the development of medical breakthroughs for unmet medical needs.
Products and Services
- Eliquis, Nurtec ODT/Vydura, Zavzpret, and Premarin family brands: Targeting cardiovascular metabolic, migraine, and women's health, these products offer innovative treatments in their respective therapeutic areas.
- Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands: Focused on infectious diseases with unmet medical needs, including vaccines for various age groups and conditions.
- Comirnaty and Paxlovid brands: At the forefront of COVID-19 prevention and treatment, offering some of the earliest and most effective vaccines and antiviral treatments against the virus. Furthermore, Pfizer is exploring potential future mRNA and antiviral products.
- Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands: Offering biosimilars and original treatments for chronic immune and inflammatory diseases, showing Pfizer’s commitment to broadening access to critical medication.
- Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands: Addressing rare and severe conditions such as amyloidosis, hemophilia, endocrine diseases, and sickle cell disease with cutting-edge biopharmaceutical treatments.
- Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands: Including sterile injectable and anti-infective medicines that play a vital role in treating various infections and conditions.
- Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands: A comprehensive list of biologics, small molecules, immunotherapies, and biosimilars for treating cancer and other severe diseases, showcasing Pfizer’s extensive contribution to oncology and other advanced therapeutic areas.
- Contract Manufacturing: In addition to its extensive pharmaceutical product lineup, Pfizer is also involved in the contract manufacturing business, leveraging its vast infrastructure and expertise to produce medicines for other entities.
Contact Information
